Boston Scientific announces favorable study data for its FARAPULSE PFA system and WATCHMAN FLX device at the AF Symposium 2025.

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant ...

SGMC Health is raising the bar in cardiac care with the introduction of a cutting-edge Cardiac Electrophysiology (EP) Lab at ...

It included a sub-analysis of 1,600 patients with atrial fibrillation who underwent device implantation either concomitantly or sequentially. The concomitant LAAC with the WATCHMAN FLX device ...

Similar stroke protection with the WATCHMAN FLX device compared to OAC irrespective ... to improve long-term outcomes for patients with atrial fibrillation," said Dr. Brad Sutton, M.D., chief ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17. In late-breaking data presentations, the ADVANTAGE AF trial for the ...

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field ...